Skip to main content

We have two economies, Jim Cramer reminded his Mad Money viewers Friday. As demonstrated in the stock market, some stocks are vulnerable to trade war news, others are not. And, Cramer said, he doesn't think there's going to be a quick and easy trade deal anytime soon. The domestic economy remains strong, but the international economy continues to struggle. The debate over which side is right will continue into next week, Cramer said, as he laid out his game plan for next week's action.

On Monday, Cramer said he'll be watching out for two things. The first is news out of Hong Kong, where protests continue. The second will be any update on iPhone sales for launch weekend. Cramer continued to recommend owning Apple (AAPL) - Get Apple Inc. Report .

Next, on Tuesday, we hear from CarMax (KMX) - Get CarMax, Inc. Report and AutoZone (AZO) - Get AutoZone, Inc. Report , along with Nike (NKE) - Get NIKE, Inc. Class B Report and uniform supplier Cintas (CTAS) - Get Cintas Corporation Report . Cramer was a buyer of AutoZone on any weakness and also recommended Cintas.

Wednesday brings earnings from KB Home (KBH) - Get KB Home Report , which is at a 52-week high, along with analyst meetings for Best Buy (BBY) - Get Best Buy Co., Inc. Report and VF Corp (VFC) - Get V.F. Corporation Report . Cramer was a fan of KB Home, now that the Federal Reserve has lowered interest rates, and of VF, which has seen strong footwear sales.

Earnings continue on Thursday with Accenture (ACN) - Get Accenture Plc Class A Report , ConAgra Foods (CAG) - Get Conagra Brands, Inc. Report and Micron Technologies (MU) - Get Micron Technology, Inc. Report . Cramer urged investors to stay away from Micron, but was bullish on Accenture.

Finally, on Friday, Boston Scientific (BSX) - Get Boston Scientific Corporation Report holds an analyst meeting and Cramer said this medical device maker rarely misses. 

Cramer and the AAP team are hopeful that a meaningful and enforceable trade deal between the world's two largest economies can be reached. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts Plus.

Chinese Consumers Step Up

Sometimes truth is stranger than fiction, Cramer told viewers. That's certainly been the case with our ongoing trade war, which has produced one anomaly after another.

When tariffs were first levied against Chinese steel, it was expected that steel prices would skyrocket. Instead, they collapsed. Sales in China for Procter & Gamble (PG) - Get Procter & Gamble Company Report were also supposed to take a hit, but instead, revenues continue to grow.

In the restaurant space, Starbucks (SBUX) - Get Starbucks Corporation Report continues to build new stores to keep up with demand, while Yum China (YUMC) - Get Yum China Holdings, Inc. Report is seeing 4% same-store sales growth. Nothing is more American than KFC, Cramer added.

When the shorts bet against Estee Lauder (EL) - Get Estee Lauder Companies Inc. Class A Report , they were quickly proven wrong, as Asia was the company's best region this quarter. That's why Cramer said he's not worried about Apple -- the iPhone 11 should be priced to provide a great value for Chinese consumers.

On Real Money, Cramer keys in on the companies and CEOs he knows best. Get more of his insights with a free trial subscription to Real Money.

Pharma Acquisitions  

Some stories are a lot more compelling than others. In the pharmaceuticals space, both Bristol-Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report and AbbVie (ABBV) - Get AbbVie, Inc. Report are trying to spur growth by making huge acquisitions, but one makes a lot more sense than the other.

Bristol-Myers is buying Celgene (CELG) - Get Celgene Corporation Report , a deal that's expected to close by the end of this year. Many investors balked at the price Bristol offered for Celgene, but Cramer estimated the acquisition is worth $120 billion when you add in the company's pipeline and synergies as a combined entity.

Scroll to Continue

TheStreet Recommends

AbbVie's acquisition is Allergan (AGN) - Get Allergan plc Report , for $63 billion. This deal is expected to close in early 2020. AbbVie's goal is to diversify and spur growth, Cramer said, and the company will be getting a lot of hot products including Botox, medical aesthetics, eye care and more.

So which deal makes the most sense? Cramer said he loves both deals, but AbbVie is his favorite, as the company overall is in better shape and pays a 6% dividend versus Bristol-Meyers at 3.3%. Additionally, AbbVie is paying for Allergan's current products, which will show instant gains, versus Bristol-Meyers, which is paying primarily for Celgene's future product pipeline. 

Executive Decision: Zscaler

For his "Executive Decision" segment, Cramer spoke with Jay Chaudhry, chairman and CEO of Zscaler (ZS) - Get Zscaler, Inc. Report , the cybersecurity company with shares that have plunged from $89 to $51 a share in recent weeks.

Chaudhry explained that they're seeing no significant change in their business. He said some of the attacks coming from legacy security vendors are exactly the kinds of things you'd expect when legacy vendors get displaced by better technology.

When asked about his comment on their conference call about larger deals taking longer to close, Chaudhry explained that Zscaler was still able to beat on both earnings and revenues and is still seeing lots of growth in their business.

Chaudhry added that Microsoft (MSFT) - Get Microsoft Corporation Report is a great partner for Zscaler and upstart CrowdStrike (CRWD) - Get CrowdStrike Holdings, Inc. Class A Report offers complimentary services to Zscaler's platform. 

Cramer Does His Homework

In his "Homework" segment, Cramer followed up on a few stocks that stumped him during earlier shows. He said that Digital Turbine (APPS) - Get Digital Turbine, Inc. Report , a speculative software company, has been around for a long time and has an exciting story, but investors may be late to the party. He recommended using limit orders and buying only after a sizable pullback.

Cramer said that talent recruiter Korn Ferry (KFY) - Get Korn Ferry Report saw highs of $65 last year, but now trades for $37. The company simply hasn't been doing well lately. Cramer said he'd wait before considering this stock. 

Lightning Round

In the Lightning Round, Cramer was bullish on Thermo Fisher Scientific (TMO) - Get Thermo Fisher Scientific Inc. Report , L3Harris Technologies (LHX) - Get L3Harris Technologies Inc Report and Funko (FNKO) - Get Funko, Inc. Class A Report .

Cramer was bearish on Kratos Defense & Security (KTOS) - Get Kratos Defense & Security Solutions, Inc. Report and HP (HPQ) - Get HP Inc. Report

Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, MSFT.